{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:18:07Z","timestamp":1772745487352,"version":"3.50.1"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine the efficacy of bortezomib in patients with lymphoid malignancy, correlating clinical response with effect on plasma cytokines and in vitro activity in primary cultures. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients received bortezomib (1.3 mg\/m<jats:sup>2<\/jats:sup>) on days 1, 4, 8, and 11 of a 3-week cycle. Plasma tumor necrosis factor alpha (TNF-\u03b1) and interleukin-6 were measured before each treatment, and bortezomib activity was examined in patient samples grown in primary culture. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Fifty-one patients received a total of 193 cycles of treatment. Twenty-four patients had mantle cell lymphoma (MCL), 13 had follicular lymphoma (FL), six had lymphoplasmacytic lymphoma, six had Hodgkin's disease (HD), and one each had diffuse large B-cell lymphoma and adult T-cell leukemia\/lymphoma. Patients were heavily pretreated with a median of four previous therapies. Significant grade 3 to 4 toxicities were thrombocytopenia (n = 22), fatigue (n = 10), and peripheral neuropathy (n = 3). Seven patients with MCL responded to treatment (one complete response, six partial responses [PRs]; overall response rate, 29%). Two patients with FL achieved a late PR 3 months after discontinuing therapy. Two patients with Waldenstr\u00f6m's macroglobulinemia and one patient with HD achieved a PR. MCL primary cultures demonstrated greater sensitivity to bortezomib than FL (median 50% effective concentration for viability, 209 nmol\/L v 1,311 nmol\/L, respectively; P = .07), which correlated with clinical response. A median reduction in plasma TNF-\u03b1 of 98% was observed in six patients with MCL who responded to bortezomib compared with a reduction of 38% in six nonresponders (P = .07). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Bortezomib demonstrates encouraging efficacy in MCL in heavily pretreated individuals. Response was associated with a reduction in plasma TNF-\u03b1 and in vitro sensitivity in a small number of patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.04.6789","type":"journal-article","created":{"date-parts":[[2006,4,11]],"date-time":"2006-04-11T00:44:39Z","timestamp":1144716279000},"page":"2105-2112","source":"Crossref","is-referenced-by-count":141,"title":["Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity"],"prefix":"10.1200","volume":"24","author":[{"given":"Sandra J.","family":"Strauss","sequence":"first","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenushka","family":"Maharaj","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hoare","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Johnson","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Radford","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Vinnecombe","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Millard","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ama","family":"Rohatiner","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Boral","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Trehu","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schenkein","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Balkwill","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon P.","family":"Joel","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Andrew","family":"Lister","sequence":"additional","affiliation":[{"name":"From the Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital; Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary's Medical School, London; Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton; Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; and Millennium Pharmaceuticals Inc, Cambridge, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10403"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/5.suppl_2.S91"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059154"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11918"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-7404(00)00012-8"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403171"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.9.3129"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205483"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1861"},{"key":"R13","unstructured":"Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071,2001-3076,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0494"},{"key":"R15","unstructured":"Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615,1999-2622,"},{"key":"R16","unstructured":"LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996,2002-5000,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"R18","unstructured":"Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145,2003-1154,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50037"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1848.1848"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(82)90051-1"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi724"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.608.608"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Treon SP, Hunter Z, Matous J, et al: Phase II study of bortezomib in relapsed\/refractory Waldenstrom's macroglobulinemia: Interim results of WMCTG 03-248. Ann Oncol 16:098,2005,  (suppl V)","DOI":"10.1182\/blood.V106.11.490.490"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2638.2638"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1038\/nature03579"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.3278.3278"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01388.x"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.499"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01390.x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.04.6789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:20:48Z","timestamp":1653513648000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.04.6789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2006,5,1]]}},"alternative-id":["10.1200\/JCO.2005.04.6789"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.04.6789","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}